XBiotech Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
35.82 M |
Public Float |
25.01 M |
XBiotech Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.64 |
Market Cap |
$318.27 M |
Shares Outstanding |
40.96 M |
Public Float |
13.14 M |
Address |
5217 Winnebago Lane Austin Texas 78744 United States |
Employees | - |
Website | http://www.xbiotech.com |
Updated | 07/08/2019 |
XBiotech, Inc. is a biopharmaceutical company, which engages in discovering and developing True Human monoclonal antibodies for treating diseases. It offers MABp1, which targets and neutralizes interleukin-1 alpha, a molecule known to promote angiogenesis, growth and spread of tumors, as well as mediate symptoms such as metabolic dysregulation, fatigue, and anxiety associated with advanced cancer. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX. |